Compare Lemonade Inc (LMND) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lemonade Inc vs Natera Inc. Common Stock — how do they compare? Lemonade Inc trades at $42.5 (market cap $3.39B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 16.8× Lemonade Inc's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Lemonade Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Lemonade Inc for 27 Days and Natera Inc. Common Stock for 0 Days on average.
| LMND | NTRA | |
|---|---|---|
Market Cap | $3.39B | $57.03B |
Volume | 1,877,282 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $96.57 | $425.64 |
52-Week Low | $43.86 | $179.42 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | $3.25B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lemonade (LMND) trades at $44.71, down 0.97% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $257M in 2022 to $738M in 2025, though remains unprofitable with a -22.43% net margin. Analyst consensus is divided with a $67 price target, while technical indicators show oversold conditions with key support at $43.
Lemonade's path to profitability by late 2026 presents opportunity, but execution risks and persistent losses require caution. Expansion into new states and AI-driven efficiency improvements support growth, yet competitive pressures and cash flow challenges remain headwinds for investors seeking exposure to insurtech disruption.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Lemonade Inc
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes.
Read more on LMND →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
